Berlin, Germany - February 4, 2025
ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded services and proprietary technologies. The platform delivers an intuitive, user-focused experience and faster access to essential information.
The new website enables visitors to efficiently and more easily explore ProBioGen's comprehensive portfolio, which includes cell line development, cell banking, process and full analytical development, GMP manufacturing, and advanced solutions for proteins, viral vectors, and vaccines. It also spotlights proprietary technologies, such as GlymaxX® and DirectedLuck®, developed to enhance efficacy, boost productivity or accelerate time to clinic.
"Our relaunched website reflects ProBioGen's commitment to innovation and partnership putting our customers first," said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen. "By focusing on clarity and ease of use, the platform empowers visitors to make faster decisions, plan projects more effectively, and drive innovation in next-generation therapies."
Explore the new website at www.probiogen.de.
About ProBioGen
ProBioGen is a Berlin-based biotech company, so called Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally.
It specializes in developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, applying proprietary technologies to improve product quality and features. It started in 1994 as a spin-off of Charité, a widely recognized hospital as one of the best in the world. 30 years later, almost 300 employees with a wealth of experience work at ProBioGen's three locations in Berlin.
Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisitions. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.
For more information about ProBioGen, follow us on LinkedIn.
ProBioGen Contact:
Dr. Gabriele Schneider
Chief Business Officer
cdmo@probiogen.de
ProBioGen Press Contact:
Sarah Wandrey
Senior Communications Manager
press@probiogen.de